Arecor Therapeutics - EASD 2024: Positive Phase I for AT278 in Type II diabetes
This Update reviews the detailed AT278 Phase I data in Type II diabetes patients presented at ESMO 2024, and also reinstates our valuation and forecasts following the recent summer fund-raise.
Arecor Therapeutics is a clinical stage drug developer, with a well-balanced portfolio of in-house and partnered programmes based on its proprietary Arestat formulation platform, and an internal focus on diabetes.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
